Yuan Zhao1,2, Bing Wan3, Tianli Zhang4, Yangyang Xu5, Hongbing Liu4,6, Tangfeng Lv4,6, Fang Zhang4,6, Ping Zhan4,6, Yong Song4,6. 1. Department of Critical Care Medicine, School of Medicine, Zhongda Hospital, Southeast University, Nanjing 210000, China. 2. Department of Respiratory Medicine, Jinling Hospital, Nanjing Medical University, Nanjing 210002, China. 3. Department of Respiratory and Critical Care Medicine, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 210002, China. 4. Department of Respiratory Medicine, Jinling Hospital, Medical School of Southeast University, Nanjing 210000, China. 5. Department of Respiratory Medicine, Jinling Hospital, Nanjing Medical University, Nanjing 210000, China. 6. Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China.
Abstract
BACKGROUND: The main aim of this study was to evaluate the efficiency of second-line chemotherapy irinotecan (CPT-11), topotecan (TPT), paclitaxel (PTX) and docetaxel (DTX) in small cell lung cancer (SCLC) patients who have failure to the first-line standard treatment. The secondary aim was to evaluate the independent prognostic factors of patients who received a second line treatment. METHODS: Retrospective analysis of 116 patients who received second-line chemotherapy. Patients were divided into 4 groups according to the therapy they were treated with, which were CPT-11, TPT, PTX and DTX. Progress free survival (PFS), overall survival (OS), objective response rate (ORR) and disease control rate (DCR) were evaluated for each group. Patients' data of clinical character and blood index were collected, and the prognostic factors were assessed both at univariate and multivariate levels. RESULTS: Patients treated with CPT-11 achieved the best median PFS and OS of 91 and 595 days, while the median PFS of TPT, PTX and DTX were 74.5, 81 and 50 days respectively. The median OS of them were 154, 168.5 and 184 days respectively. The survival curves of OS were significantly different (P=0.0069). The reaction to second-line therapy is positively correlate to the reaction to first-line therapy (P=0.012). In the multivariate analysis, treatment free interval (TFI) <90 days, lactate dehydrogenase (LDH) ≥225 U/L, neutrophil-to-lymphocyte ratio (NLR) ≥3.5 were identified as independent risk factors for poor prognosis in second-line SCLC patients. CONCLUSIONS: Second-line chemotherapy with TPT in SCLC patients may provide better overall survival benefits. TFI <90 days, LDH ≥225 U/L and NLR ≥3.5 are independent risk factors for second-line SCLC patients. 2019 Translational Lung Cancer Research. All rights reserved.
BACKGROUND: The main aim of this study was to evaluate the efficiency of second-line chemotherapy irinotecan (CPT-11), topotecan (TPT), paclitaxel (PTX) and docetaxel (DTX) in small cell lung cancer (SCLC) patients who have failure to the first-line standard treatment. The secondary aim was to evaluate the independent prognostic factors of patients who received a second line treatment. METHODS: Retrospective analysis of 116 patients who received second-line chemotherapy. Patients were divided into 4 groups according to the therapy they were treated with, which were CPT-11, TPT, PTX and DTX. Progress free survival (PFS), overall survival (OS), objective response rate (ORR) and disease control rate (DCR) were evaluated for each group. Patients' data of clinical character and blood index were collected, and the prognostic factors were assessed both at univariate and multivariate levels. RESULTS: Patients treated with CPT-11 achieved the best median PFS and OS of 91 and 595 days, while the median PFS of TPT, PTX and DTX were 74.5, 81 and 50 days respectively. The median OS of them were 154, 168.5 and 184 days respectively. The survival curves of OS were significantly different (P=0.0069). The reaction to second-line therapy is positively correlate to the reaction to first-line therapy (P=0.012). In the multivariate analysis, treatment free interval (TFI) <90 days, lactate dehydrogenase (LDH) ≥225 U/L, neutrophil-to-lymphocyte ratio (NLR) ≥3.5 were identified as independent risk factors for poor prognosis in second-line SCLC patients. CONCLUSIONS: Second-line chemotherapy with TPT in SCLC patients may provide better overall survival benefits. TFI <90 days, LDH ≥225 U/L and NLR ≥3.5 are independent risk factors for second-line SCLC patients. 2019 Translational Lung Cancer Research. All rights reserved.
Entities:
Keywords:
Second-line therapy; docetaxel; irinotecan; paclitaxel; prognostic factor; small cell lung cancer (SCLC); topotecan
Authors: J von Pawel; J H Schiller; F A Shepherd; S Z Fields; J P Kleisbauer; N G Chrysson; D J Stewart; P I Clark; M C Palmer; A Depierre; J Carmichael; J B Krebs; G Ross; S R Lane; R Gralla Journal: J Clin Oncol Date: 1999-02 Impact factor: 44.544
Authors: Joachim von Pawel; Robert Jotte; David R Spigel; Mary E R O'Brien; Mark A Socinski; Jörg Mezger; Martin Steins; Léon Bosquée; Jeffrey Bubis; Kristiaan Nackaerts; José M Trigo; Philip Clingan; Wolfgang Schütte; Paul Lorigan; Martin Reck; Manuel Domine; Frances A Shepherd; Shaoyi Li; Markus F Renschler Journal: J Clin Oncol Date: 2014-11-10 Impact factor: 44.544
Authors: Jeffrey W Allen; James Moon; Mary Redman; Shirish M Gadgeel; Karen Kelly; Philip C Mack; Hanna M Saba; Mohamed K Mohamed; Mohammad Jahanzeb; David R Gandara Journal: J Clin Oncol Date: 2014-07-07 Impact factor: 44.544